IO Biotech, Inc. (IOBT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
IOBT currently has 66.9M outstanding shares. with significant dilution risk as 128M authorized shares could dilute existing holders by 190.5%. The company has minimally diluted shareholders by 1.61% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 14, 2025 |
10-Q filing | 66.9M shares outstanding |
67M | 130M |
| Aug 14, 2025 |
10-Q filing | 65.9M shares outstanding |
66M | 130M |
| Jul 24, 2025 |
S-3 filing: IO Biotech, Inc. is offering up to 4,221,867 shares of common stock issuable upon the exercise of warrants held by the selling stockholders. |
66M | 130M |
| May 23, 2025 |
S-3 filing: IO Biotech, Inc. is offering up to 5,623,664 shares of common stock issuable upon the exercise of warrants held by selling stockholders. |
66M | 120M |
| May 14, 2025 |
10-Q filing | 65.9M shares outstanding |
66M | 120M |
| Mar 31, 2025 |
10-K filing | 65.9M shares outstanding |
66M | 120M |
| Nov 12, 2024 |
10-Q filing | 65.9M shares outstanding |
66M | 120M |
| Aug 13, 2024 |
10-Q filing | 65.9M shares outstanding |
66M | 120M |
| May 14, 2024 |
10-Q filing | 65.9M shares outstanding |
66M | 120M |
| Mar 05, 2024 |
10-K filing | 65.9M shares outstanding |
66M | 120M |
| Nov 13, 2023 |
10-Q filing | 65.9M shares outstanding |
66M | 120M |
| Aug 30, 2023 |
S-3 filing: IO Biotech, Inc. is offering up to 74,131,294 shares of common stock by selling stockholders, consisting of 37,065,647 shares held by the selling stockholders and 37,065,647 shares issuable upon the exercise of warrants. |
66M | 120M |
| Aug 11, 2023 |
10-Q filing | 65.9M shares outstanding |
66M | 6.5M |
| May 11, 2023 |
10-Q filing | 28.8M shares outstanding |
29M | 6.5M |
| Mar 14, 2023 |
10-K filing | 28.8M shares outstanding |
29M | 6.5M |
| Feb 03, 2023 |
S-3 filing: IO Biotech, Inc. files an S-3 to offer common stock, preferred stock, debt securities, warrants, rights to purchase common stock, preferred stock, debt securities or units, as well as units that include any of these securities, with an aggregate offering price of up to $250,000,000. |
29M | 6.5M |
| Nov 09, 2022 |
10-Q filing | 28.8M shares outstanding |
29M | 6.5M |
| Aug 11, 2022 |
10-Q filing | 28.8M shares outstanding |
29M | 6.5M |
| May 16, 2022 |
10-Q filing | 28.8M shares outstanding |
29M | 6.5M |
| Mar 31, 2022 |
10-K filing | 28.8M shares outstanding |
29M | 6.5M |
| Dec 17, 2021 |
10-Q filing | 28.8M shares outstanding |
29M | 6.5M |
| Nov 01, 2021 |
S-1/A filing: S-1/A filing describes the issuance of Class B preference shares, conversion of convertible notes, equity-based compensation, currency translation, and net loss. It includes information about existing and new stockholders, shares purchased, total consideration, and average price per share, based on an assumed IPO price of $15.50 per share. |
19M | 6.5M |
| Oct 26, 2021 |
S-1/A filing: This is an S-1/A filing from IO Biotech ApS detailing recent sales of unregistered securities, including convertible notes, preference shares, and warrants. |
N/A | 650K |
| Oct 15, 2021 |
S-1 filing: This is an S-1 filing. |
N/A | 0 |